



Pharmacovigilance and Risk Management Strategies Conference

January 22-24 | Omni Shoreham Hotel | Washington, DC

PROGRAM CO-CHAIRS

Stella C. F. Blackburn, MD, MA, MSc, FFPM, FISPE, FRCP

Vice President, Global Head of Risk Management
IQVIA, United Kingdom

William W. Gregory, PhD

Senior Director, Worldwide Safety and Regulatory
Pfizer Inc

PROGRAM COMMITTEE

Mariette Boerstoeel-Streefland, MD, MBA, MS

Senior Vice President, Head Global Drug Safety
Shire

Mick Foy

Group Manager, Vigilance Intelligence and Research
Group
Medicines and Healthcare products Regulatory Agency
(MHRA), United Kingdom

E. Stewart Geary, MD

Senior Vice President, Chief Medical Officer, Director,
Corporate Medical Affairs HQ
Eisai Co., Ltd., Japan

Lisa Melanie Harinstein, PharmD, BCPS

Safety Evaluator, Division of Pharmacovigilance-I, Office
of Surveillance and Epidemiology
CDER, FDA

Stephen Knowles, MD, MRCP

Senior Director, Global Patient Safety, Medical and
Benefit Risk Management
Eli Lilly and Company

Barbara A. Morollo, RN

Head, Pharmacovigilance Operations
Moderna Therapeutics

Simone P. Pinheiro, PhD

Lead Epidemiologist
FDA

Michael Richardson, MD, FFPM

International Head GPV&E and EU Qualified Person for
Pharmacovigilance
Bristol-Myers Squibb, United Kingdom

Annette Stemhagen, DrPH, FISPE

Senior Vice President, Safety, Epidemiology, Registries
and Risk Management
UBC, An Express Scripts Company

Lesley Wise, PhD, MSc

Managing Director
Wise Pharmacovigilance and Risk Management Ltd.,
United Kingdom

Overview

DIA's *Pharmacovigilance and Risk Management Strategies Conference* provides the strongest context, background, updates, new developments, and future direction for regulations and guidance on safety, pharmacovigilance, and risk management strategies that cannot be found in any other meeting. The content of this event is developed by top experts from the biopharmaceutical industry and global regulatory agencies, and DIA will convene the best speakers from around the world to discuss the current challenges and issues that matter most to professionals working in the field.

Highlights

- Global Regulatory Updates
- Daily Keynote Speakers
- Luncheon Round Table Discussions with Key Thought Leaders
- Special Hot Topic Session: Key Hot Topics Examined In-Depth
- Tabletop Exhibits and Networking Opportunities

Who Should Attend

Professionals involved in:

- Drug Safety/Pharmacovigilance
- Risk Management, including Risk Evaluation and Mitigation Strategies (REMS)
- Benefit-risk assessment and communication
- Medical Product Safety Assessment
- Regulatory Affairs
- Clinical Research
- Pharmacoepidemiology
- Post-market studies and Real World Evidence generation
- Customer Engagement Programs, including Patient Support Programs
- Medical Information, Medical Communications
- Health Outcomes



800 Enterprise Road
Suite 200
Horsham, PA 19044 USA

#PVRMS18 | DIAglobal.org

As of November 29, 2017.

| Schedule At-A-Glance

SHORT COURSES | SUNDAY, JANUARY 21

7:30AM-5:00PM Short Course Registration

7:30-8:30AM Continental Breakfast, Exhibits, and Networking

9:00AM-5:00PM **Short Course 1:** PBRER

9:00AM-5:00PM **Short Course 2:** Pharmacovigilance and Risk Management Planning

9:00AM-12:30PM **Short Course 3:** Pharmacovigilance Inspections Part 1: Readiness, Conducting, Findings, and Report-Outs

12:30-1:30PM Luncheon for Short Course Attendees

1:30-5:00PM **Short Course 4:** Pharmacovigilance Inspections Part 2: Response, Measurement, Resolution, and Tracking

DAY ONE | MONDAY, JANUARY 22

7:00AM-5:30PM Registration

7:15-8:15AM Continental Breakfast, Exhibits, and Networking

8:15-8:30AM **DIA Opening Remarks**

8:30-8:45AM **Welcome Remarks**

8:45-9:30AM **Opening Keynote:** Patient Advocacy in Rare Disease: Duchenne Muscular Dystrophy

9:30-11:00AM **Session 1:** FDA Updates

11:00-11:30AM Refreshment, Exhibits, and Networking Break

11:30AM-12:30PM **Session 2:** The New ICH

12:30-2:00PM Luncheon and Round Table Discussions

2:00-3:30PM **Session 3:** Operational Hot Topic: Machine Learning/Artificial Intelligence in Pharmacovigilance

3:30-4:00PM Refreshment, Exhibits, and Networking Break

4:00-5:30PM **Session 4:** Combination Products

5:30-6:30PM Networking and Exhibitor Reception

6:30-9:30PM Dine Arounds

| Schedule At-A-Glance

DAY TWO | TUESDAY, JANUARY 23

7:30AM-6:00PM	Registration
7:30-8:30AM	Continental Breakfast, Exhibits, and Networking
8:30-8:45AM	Welcome Remarks Day Two
8:45-9:30AM	Day Two Keynote: Data Rich, Information Poor – Can We Turn Health Records into a Truly Learning Healthcare System?
9:30-11:00AM	Session 5: EU Updates
11:00-11:30AM	Refreshment, Exhibits, and Networking Break
11:30AM-12:45PM	Session 6: Clinical Trial Issues
12:45-2:00PM	Luncheon, Exhibits, and Round Table Discussions
2:00-2:45PM	Mid-Day Keynote
2:45-4:15PM	Session 7: Update on New Treatments
4:15-4:45PM	Refreshment, Exhibits, and Networking Break
4:45-6:00PM	Session 8: Advanced Therapeutics Pharmacovigilance and Risk Management

DAY THREE | WEDNESDAY, JANUARY 24

7:00AM-3:30PM	Registration
7:00-8:00AM	Continental Breakfast, Exhibits, and Networking
8:00-8:15AM	Welcome Remarks
8:15-9:00AM	Day Three Keynote: Innovative Pharmacovigilance When Resources are Scarce
9:00-10:00AM	Session 9: Advanced Technologies
10:00-10:45AM	Refreshment, Exhibits, and Networking Break
10:45AM-12:15PM	Session 10: Regional Updates
12:15-12:30PM	Q&A
12:30-1:45PM	Luncheon, Exhibits, and Networking
1:45-3:15PM	Session 11: Hot Topics
3:15-3:30PM	Closing Remarks
3:30PM	Conference Adjourned

Learning objectives

At the conclusion of this conference, participants should be able to:

- Employ the current regulatory framework for pharmacovigilance in key markets, including the US and the changing EU
- Examine the influence of recent regulatory developments and expectations in Japan, Canada, and Eurasia on safety and pharmacovigilance practice
- Discuss changes in pharmacovigilance and risk management resulting from the emergence of new and advanced technologies and therapies such as CAR-T cells, monoclonal antibodies, and gene therapy
- Describe pharmacovigilance and risk management considerations and approaches for combination products and rare disease therapies
- Apply frameworks and learnings from recent government and industry initiatives to improve safety monitoring and reporting in clinical trials
- Discuss challenges posed by the changing nature of safety data and the implications of new guidelines, such as the developing ICH E19 Guideline, and new approaches to pharmacovigilance and risk management, such as Artificial Intelligence/Machine Learning

TO ACCESS MY TRANSCRIPT

- Visit DIAglobal.org, select “Sign in” and you will be prompted for your user ID and password
- Choose MENU, found in the upper left corner
- Under CONFERENCES select “Continuing Education”
- Select the blue “My Transcript” button followed by “Credit Request” to process your credit request for the course

ACCESS PRESENTATIONS

- Visit DIAglobal.org
- Select ‘Sign in’ at the top right
- Enter your User ID and Password
- Go to ‘My Account’
- View ‘My Presentation’

Please Note: DIA User ID and Password are needed to access presentations. If you have forgotten your DIA User ID and Password, or this is your first time logging into the DIA website, please use our Login Reminder. **Presentations will be available for six months post conference.*

SAVE THE DATE!



DIA 2018

GLOBAL ANNUAL MEETING
BOSTON, MA | JUNE 24-28

DIAglobal.org/DIA2018



SHORT COURSES | SUNDAY, JANUARY 21

8:00AM-5:00PM	Short Course Registration
9:00AM-5:00PM	Short Course 1: PBRER Instructors Christina Phan Associate Director Safety Evaluation and Reporting, Worldwide Safety and Regulatory Pfizer, Inc Alison Turney, PharmD Surveillance Business Process Advisor, Global Patient Safety Eli Lilly and Company Valerie E. Simmons, MD, FFPM EU QPPV, Global Patient Safety Eli Lilly and Company Ltd., United Kingdom The instructors for this short course draw on experience from both direct involvement in the development of the ICH guideline itself, as well as from experts with extensive experience in actual implementation. This short course will cover the background and expectations behind key sections of the guideline and will provide an in-depth interpretation from the perspective of the expert working group that developed the concept. Based on this theoretic foundation, the course will then move to more practical aspects of implementation and lessons learned from experience since the PBRER format was first introduced. This will include the latest thinking and updates from the EU. The intent of this course is to be interactive and to tailor to your needs as much as possible. Questionnaires will therefore be sent to you to assess expectations based on level of experience as well as any key questions you wish the instructors to specifically address with the aim that answers are developed together in a coaching environment. Learning Objectives At the conclusion of this short course, participants should be able to: • Discuss the main principles defined in the ICH E2C(R2) guideline • Describe the structure and content of the new PBRER • Explain the regulatory authority expectations of the PBRER • Recognize how to implement the PBRER to encompass multiple functions • Discuss and evaluate the practical aspects in the preparation of the PBRER
9:00AM-5:00PM	Short Course 2: Pharmacovigilance and Risk Management Planning Instructors Stella C.F. Blackburn, MD, FRCP, FISPE, FFPM Vice President, Global Head of Risk Management IQVIA, United Kingdom William W. Gregory, PhD Senior Director, Worldwide Safety and Regulatory Pfizer Inc This full-day short course will focus on basic aspects of the regulatory framework for pharmacovigilance in the context of risk management planning and on the practical aspects of managing biopharmaceutical product risks in the context of benefits and the healthcare delivery system. The main focus will be on the EU and US situations, but this will be supplemented with experience gained in other selected jurisdictions. Learning Objectives At the conclusion of this short course, participants should be able to: • Discuss similarities and differences in risk management planning in the three ICH regions and other selected jurisdictions • Describe the differences between important identified risks and important potential risks • Outline the basic structure and contents of an EU Risk Management Plan (in the context of a Risk Management System) and a Risk Evaluation and Mitigation Strategy (REMS) • Discuss primary and non-routine tools for managing product risks, how the effectiveness of a selected tool is assessed, and points to consider for the modification, revision, or release of a given non-routine intervention
12:30-1:30PM	Luncheon for Short Course Attendees
9:00AM-12:30PM	Short Course 3: Pharmacovigilance Inspections Part 1: Readiness, Conducting, Findings, and Report-Outs Instructors Helen Powell Principal Consultant NDA Regulatory Science Ltd., United Kingdom Shiferaw Kibriye, PharmD Medical Quality Assurance, Head of Inspection Management Pfizer Inc Richard Abate, MS, RPh Lead Consumer Safety Officer FDA Marcia Gelber, PharmD, RPh Pharmacist, DHHS FDA Michael Richardson, MD, FFPM International GPV&E and EU QPPV Bristol-Myers Squibb, United Kingdom If a government investigator knocks on your door today, would your organization be ready for an inspection of your pharmacovigilance system? This short course will help familiarize you with the FDA inspection process so that an inspection can be effectively hosted and proactively managed. Hear two FDA experts and an EU expert explain how to be inspection ready, the Inspector's expectations, and common missteps that result in observations. In turn, learn perspectives from an industry veteran on what to do before and during an inspection. Course instructors will share practical and actionable commentary that you can use to improve and sustain your pharmacovigilance quality system. Learning Objectives At the conclusion of this short course, participants should be able to: • Explain the purpose behind pharmacovigilance inspections and their benefit(s) • Describe the US and EU inspection processes and the differences/commonalities between the two • Explain how to be inspection-ready • Outline common inspection observations, including common EU findings • Interpret messaging in FDA Untitled Letters and Warning Letters and EU inspection findings

SHORT COURSES | SUNDAY, JANUARY 21

1:30-5:00PM

Short Course 4: Pharmacovigilance Inspections Part 2: Response, Measurement, Resolution, and Tracking

**This short course follows on from the morning course, but can also be taken as a separate session.*

Instructors

Vicki Edwards, RPh

Vice President, Pharmacovigilance
Excellence and QPPV
AbbVie, Inc., United Kingdom

Shiferaw Kibriye, PharmD

Medical Quality Assurance. Head of
Inspection Management
Pfizer Inc

Helen Powell

Principal Consultant
NDA Regulatory Science Ltd., United Kingdom

The regulatory authority has just completed an inspection of your pharmacovigilance system and left you with a list of inspection observations. As you wait to receive the inspection report, when and how should you respond? Well-reasoned, complete, and timely responses are key to more positive outcomes of an inspection – in fact, they may make a difference in the final classification of an error or the type of regulatory correspondence issued. This short course will familiarize you with the principles and practical methods of planning and preparing an effective response to inspection observations, including: coordinated response preparation, assessment of underlying causes, development and implementation of corrective and preventive action plans (CAPAs), measurement, and tracking. Through hands-on case studies, you will have the opportunity to develop responses and action plans for the US and EU and to receive feedback on their work from regulators and qualified professionals.

Learning Objectives

At the conclusion of this short course, participants should be able to:

- Describe common pharmacovigilance inspection observations
- Explain principles and guidelines for planning and preparing responses to inspection observations
- Plan and conduct a response to inspection observations, including development of a CAPA, measurement, and tracking

DAY ONE | MONDAY, JANUARY 22

7:15AM-5:30PM

Registration

7:15-8:15AM

Continental Breakfast, Exhibits, and Networking

8:15-8:30AM

DIA Opening Remarks

8:30-8:45AM

Welcome Remarks

Session Co-Chairs

Stella C.F. Blackburn, MD, FRCP, FISPE, FFPM
Vice President, Global Head of Risk
Management
IQVIA, United Kingdom

William W. Gregory, PhD

Senior Director, Worldwide Safety and Regulatory
Pfizer Inc

8:45-9:30AM

Opening Keynote: Patient Advocacy in Rare Disease: Duchenne Muscular Dystrophy

Session Chair

William W. Gregory, PhD

Senior Director, Worldwide Safety and Regulatory
Pfizer Inc

Rare diseases present special challenges for patients, caregivers, and those who seek to develop and provide safe and effective treatments. One disease that presents such challenges is Duchenne Muscular Dystrophy (DMD), a genetic disorder that is characterized by progressive muscle degeneration and weakness caused by an abnormality in the dystrophin complex in muscle fiber. Development of safe and effective biopharmaceutical interventions has been enigmatic. This session will provide an overview of this devastating disease, patient advocacy efforts, and the partnership network that has emerged to facilitate development of evidence-based interventions.

Christine McSherry

Executive Director
The Jett Foundation

DAY ONE | MONDAY, JANUARY 22

9:30-11:00AM

Session 1: FDA Updates

Session Chair

Gerald J. Dal Pan

Director, Office of Surveillance and Epidemiology
CDER, FDA

FDA representatives will provide updates from the Office of Surveillance and Epidemiology (OSE) within CDER and the Office of Biostatistics and Epidemiology in CBER. Topics will include post-marketing safety monitoring, an overview of pharmacoepidemiology, pharmaceutical risk management, medication error prevention, and updates on safety surveillance from the Office of Generic Drugs.

New Developments in Pharmacovigilance

Gerald J. Dal Pan

Director, Office of Surveillance and Epidemiology
CDER, FDA

An FDA Update on Pharmacovigilance and Risk Management Approaches for CBER-Regulated Biologic Products

Steven Anderson PhD, M.P.P.

Director, Office of Biostatistics and Epidemiology
CBER, FDA

Experiences in Safety and Surveillance of Generic Drugs

John Peters, MD

Deputy Director, Office of Generic Drugs
CDER, FDA

Howard D. Chazin, MD, MBA

Medical Officer, Clinical Safety and Surveillance
Office of Generic Drugs
CDER, FDA

11:00-11:30AM

Refreshments, Exhibits, and Networking Break

11:30AM-12:30PM

Session 2: The New ICH

Session Chair

William W. Gregory, PhD

Senior Director, Worldwide Safety and Regulatory
Pfizer Inc

Since 1990, the International Conference on Harmonisation (ICH) has provided a consensus forum for drug regulators and the pharmaceutical industry to develop harmonized of scientific and technical requirements for registration of innovative pharmaceutical products. In October 2015, ICH announced organizational and process changes to expand formal participation of organizations beyond the EU, Japan, and the US. Further changes to the face of global biopharmaceutical product development were made in June 2017. This session will provide an overview of the current ICH. In addition, regulator and industry perspectives will be presented on global harmonization of a new topic, E-19 (optimization of safety data collection).

Overview of the Current ICH

Amanda Marie Roache, MS

Operations Research Analyst, OSP
CDER, FDA

The New ICH E19 Guideline on Optimization of Safety Data Collection (in Development): Regulatory Perspective

Ellis Unger, MD

Director, Office of Drug Evaluation I, OND

12:30-2:00PM

Luncheon and Round Table Discussions

2:00-3:30PM

Session 3: Operational Hot Topic: Machine Learning/Artificial Intelligence in Pharmacovigilance

Session Co-Chairs

Mariette Boerstoele-Streefland, MD

Senior Vice President, Head Global Drug Safety
Shire

Bruce Donzanti, PhD

Senior Group Director
Global Pharmacovigilance Innovation Policy
Genentech Inc., A Member of the Roche Group

This session will provide a brief introduction on the need for new technologies to address the growing concerns around the ability to assess the ever-increasing volumes of data for valuable safety information, the applicability of ML/AI to address this concern, and will bring in perspectives from regulatory authorities, pharma industry, and a technology innovator, to conclude with a panel discussion on where we are going with the application of ML/AI in pharmacovigilance.

Bruce Donzanti, PhD

Senior Group Director
Global Pharmacovigilance Innovation Policy
Genentech Inc., A Member of the Roche Group

New Kid on the Block: Machine Learning and Why it's Important for Pharmacovigilance

Shaun Comfort, MD, MBA

Associate Director and Senior Safety Science
Leader IIDO
Genentech, A Member of the Roche Group

Machine Learning Use Cases

Elenee Argentinis

Offering Leader, IBM Watson for Patient Safety
Watson Health Life Sciences Solutions

Shaun Comfort, MD, MBA

Associate Director and Senior Safety Science
Leader IIDO
Genentech, A Member of the Roche Group

Regulatory Perspective on Machine Learning in Pharmacovigilance

Robert Ball, MD, MPH

Deputy Director, Office of Surveillance and Epidemiology
CDER, FDA

Mick Foy

Group Manager, Vigilance Intelligence and Research Group
Medicines and Healthcare products Regulatory Agency (MHRA), EU

Panel Q&A

DAY ONE | MONDAY, JANUARY 22

3:30-4:00PM	Refreshments, Exhibits, and Networking Break
4:00-5:30PM	Session 4: Combination Products Session Chair Lisa Melanie Harinstein, PharmD, BCCCP, BCPS Team Leader, Division of Pharmacovigilance I, OSE CDER, FDA Combination products are therapeutic and diagnostic products that combine drugs, devices, and or biological products. Because combination products involve multiple components, they are associated with new regulatory, policy, development, and review challenges. In this session, we explore some of these emerging challenges with combination products, such as adverse event reporting and principles of human factor studies during the development of combination products. Safety Reporting Rule for Combination Products Representative Invited FDA Technical Specifications for Safety Reporting of Combination Products Suranjan De, MBA, MS Deputy Director, Regulatory Science, OSE CDER, FDA Khaudeja Bano, MD, MS Senior Medical Director, Medical Affairs, Diagnostics Abbott Laboratories
5:30-6:30PM	Networking and Exhibits Reception
6:30-9:00PM	Dine Arounds

DAY TWO | TUESDAY, JANUARY 23

7:30AM-6:00PM	Registration
7:30-8:30AM	Continental Breakfast, Exhibits, and Networking
8:30-8:45AM	Welcome Remarks
8:45-9:30AM	Day Two Keynote: Data Rich, Information Poor – Can We Turn Health Records into a Truly Learning Healthcare System? Session Chair Stella C.F. Blackburn, MD, FRCP, FISPE, FFPM Vice President, Global Head of Risk Management IQVIA, United Kingdom We are being deluged by data from many different sources, but are we using it to improve outcomes for patients? This session will cover what a learning healthcare system is and where we are in implementation. It will also explore personalized medicine and whether regulators, payers, and healthcare systems can keep up with the challenges of rapid progress in medicine. Hans-Georg Eichler, MD, MSc Senior Medical Officer European Medicines Agency, European Union
9:30-11:00AM	Session 5: EU Updates Session Co-Chairs Mick Foy Group Manager, Vigilance Intelligence and Research Group Medicines and Healthcare products Regulatory Agency (MHRA), European Union Hans-Georg Eichler, MD, MSc Senior Medical Officer European Medicines Agency, European Union Regulations and expectations for pharmacovigilance in the EEA continue to evolve. This session will explore recent developments related to post-marketing pharmacovigilance as well as the practice of drug safety during clinical trials. The focus will be on the evolving situation in the EEA, set in a global context. Mick Foy Group Manager, Vigilance Intelligence and Research Group Medicines and Healthcare products Regulatory Agency (MHRA), European Union Vicki Edwards QPPV and Head of Affiliate Vigilance Excellence AbbVie, Inc., United Kingdom Valerie E. Simmons MD, FFPM EU QPPV, Global Patient Safety Eli Lilly and Company Ltd.
11:00-11:30AM	Refreshments, Exhibits, and Networking Break

DAY TWO | TUESDAY, JANUARY 23

11:30AM-12:45PM

Session 6: Clinical Trial Issues

Session Chair

Annette Stenhagen, DrPH, FISPE

Senior Vice President, Safety, Epidemiology, Registries and Risk Management
UBC, An Express Scripts Company

The current regulatory framework and expectations for good pharmacovigilance practices are changing in key markets, which create new challenges for all stakeholders. This session will examine the expanding importance of patient perspectives on toleration as the safety profile of an investigational product is developed. In addition, progress on global harmonization of pragmatic safety requirements will be addressed.

Use of Common Toxicity AE Terminology and Patient-Reported Outcomes in Clinical Trials

Sandra Mitchell, PhD, CRNP

Research Scientist and Program Director, Outcomes Research Branch, Division of Cancer Control and Population Sciences
National Cancer Institute

Global Harmonization of Pragmatic Safety Requirements, with Information from the Transcelerate Project

Robert M. Baker

Vice President, Global Patient Safety
Eli Lilly & Company

Sadiqa Hafeez Mian, MD, MPH

Head Safety Management
Amgen Inc.

Effect on the Clinical Trial Regulations on Post-Authorization Safety Studies (PASS)

Michelle Bulliard, BSN

Vice President, Global Head Real-World Evidence Strategy Unit
IQVIA, Switzerland

12:45-2:00PM

Luncheon, Exhibits, and Round Table Discussions

2:00-2:45PM

Mid-Day Keynote

Session Chair

Simone P. Pinheiro, PhD

Lead Epidemiologist
FDA

The FDA is committed to facilitating rapid development, review and action on promising cancer treatments. This exciting DIAmond session will discuss recent progresses and novel approval pathways for oncology therapeutic products, including patient-centered approaches and the evolving role of real world evidence. This session will also discuss the Oncology Center of Excellence, developed as part of the 21st Century CURES Act, and its role in the development of regulatory approaches to expedite drug development. This 45-minute session will be composed of two presentations followed by Q&A.

Novel Approaches in Oncology Products

Sean Khozin, MD, MPH

Associate Director (Acting), Oncology Center of Excellence
CDER, FDA

Oncology Center of Excellence

Tamy Kim, PharmD

Associate Director, Regulatory Affairs, Office of Hematology and Oncology Products, OCE (Acting)
CDER, FDA

2:45-4:15PM

Session 7: Update on New Treatments

Session Chair

Stella C.F. Blackburn, MD, FRCP, FISPE, FFPM

Vice President, Global Head of Risk Management
IQVIA, United Kingdom

Pharmacovigilance is similar to a detective story. We are trying to determine whether the adverse event is due to a drug, the diseases the patient is being treated for or something intrinsic to the patient. To do this we need an understanding of both the drug mechanisms of action and the context in which drug is used. New classes of treatments are being developed all the time with increasingly complex and specific mechanisms. This session will provide an overview of three emerging therapies from a clinical point of view: CAR-T cells, monoclonal antibodies – targeted therapies and checkpoint inhibitors – and gene therapy.

David Chonzi

Vice President, Patient Safety and Risk Management
Kite, A Gilead Company

Jacques P. Tremblay, PhD

Deputy Editor, Molecular Therapy and Cell Transplantation; Professor, Department of Molecular Medicine
Laval University

4:15-4:45PM

Refreshments, Exhibits, and Networking Break

4:45-6:00PM

Session 8: Advanced Therapeutics Pharmacovigilance and Risk Management

Session Chair

Barbara Morollo, RN

Head, Pharmacovigilance Operations
Moderna Therapeutics

Advanced therapy medicinal products (ATMPs), which include gene therapy medicinal products (GTMPs), somatic cell therapy medicinal products, and tissue-engineered products, are at the cutting edge of innovation and offer patients hope for various diseases for which there are limited or no therapeutic options. The development of ATMPs has sparked considerable interest and debate as there are many unknowns and uncertainties concerning the effects or responses these therapies may evoke, especially in the case of genetic manipulation.

This session will examine the challenges associated with monitoring safety and the benefit-risk of these therapies, both short-term and long-term, and explore the complexities associated with determining the safety profile and benefit-risk across common delivery platforms such as gene therapy vectors and lipid nanoparticle delivery systems.

Common Technical Platforms: Benefit-Risk Determination and Risk Management

Barbara Morollo, RN

Head, Pharmacovigilance Operations
Moderna Therapeutics

Jaspal Ahluwalia, MD

Medical Officer
FDA

Adrian Dana, MD

Vice President, Global Patient Safety and Risk Management at Alnylam
Alnylam Pharmaceuticals Cambridge

Michael Richardson, MD, FFPM

International GPV&E and EU QPPV
Bristol-Myers Squibb, United Kingdom

DAY THREE | WEDNESDAY, JANUARY 24

7:00AM-3:30PM	Registration
7:00-8:00AM	Continental Breakfast, Exhibits, and Networking
8:00-8:15AM	Welcome Remarks
8:15-9:00AM	Day Three Keynote: Innovative Pharmacovigilance when Resources are Scarce Session Chair Lesley Wise, PhD, MSc Managing Director Wise Pharmacovigilance and Risk Management Ltd., United Kingdom Pharmacovigilance capacity building in low- to middle-income countries requires innovative methods and a willingness to prioritize in a different way to the countries where PV guidances are often first issued. The health considerations are different, the communication technologies are different, and public health emergencies often stretch the scarce resources. Eric Perakslis, PhD, will share his perspectives and experience from working with a range of NGOs including MSF and developing data collection systems during the Ebola crisis. Keynote Speaker Eric D. Perakslis, PhD Senior Vice President, Informatics Takeda Pharmaceuticals
9:00-10:00AM	Session 9: Advanced Technologies Session Chair Stephen Knowles, MD, MRCP Senior Director, Global Patient Safety, Medical and Benefit Risk Management Eli Lilly and Company The use of advanced technologies in the management of chronic diseases and monitoring patients in clinical trials is increasing. For example, the use of mobile apps to aid the control of diabetes, the use of wearable technologies to monitor patient sleep and activity during clinical trials, and implantable biosensors which allow continuous monitoring of body chemicals. This session will bring scientific expert and patient perspectives together in a discussion of these new technologies and the impact they are having, and will have, on patient monitoring and patient experience. The Use of Wearable Technologies in Clinical Trials to Monitor Movement and Sleep/Wake Patterns Gary Zammit, PhD, MS President and CEO Clinilabs Inc. Sara Loud, MBA, MS Chief Operating Officer Accelerated Cure Project
10:00-10:45AM	Refreshments, Exhibits, and Networking Break
10:45AM-12:15PM	Session 10: Regional Updates Session Chair E. Stewart Geary, MD Senior Vice President, Chief Medical Officer, Director, Corporate Medical Affairs HQ Eisai Co., Ltd. This session focuses on countries or regions where pharmacovigilance regulations are in transition or where recent updates can present compliance issues for clinical trial Sponsors or Marketing Authorization Holders. The Eurasian Economic Union (EAEU), which includes Russia and a number of states in northern Eurasia, now has a Good Pharmacovigilance Practice (GVP) guideline and requirement for a QPPV, which will be described and explained. In Japan the "Three Officer System" is undergoing revisions in the face of a number of compliance issues that have surfaced in that country and the countries Good Postmarketing Survey Practice (GPSP) is also being modified. An update on the implementation of Vanessa's Law (the Protecting Canadians from Unsafe Drugs Act), one of the most significant changes to the Canadian Food and Drug Act in 50 years, and its implications for pharmacovigilance in that country will also be presented. The Evolving Situation in Japan: The "Three Officer System" and GPSP Shinobu Uzu Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan Modernization Efforts in Canada: The Regulatory Review of Drugs and Devices and Vanessa's Law Melissa Hunt, MSc Scientific Manager Health Canada CRO Perspectives on New PV Requirements in the EAEU Annette S. Williams, MBA, RPh Vice President, Lifecycle Safety IQVIA What New EAEU PV Obligations Mean for a Global Company with a Focus on Russia Tatyana Prokhorova, MD, PhD EAEU/Ukraine QPPV, Cluster Safety Lead Pfizer LLC, Russia
12:15-12:30PM	Q&A
1:45-3:15PM	Luncheon, Exhibits, and Networking
	Session 11: Hot Topics Session Chair Michael Richardson International GPV&E and EU QPPV Bristol-Myers Squibb, United Kingdom Vicki Edwards QPPV and Head of Affiliate Vigilance Excellence AbbVie, Inc. Representative Invited Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Digital Approach to Risk Minimization Mark Perrott, PhD Head of Development Consulting Pope Woodhead & Associates Ltd, United Kingdom Value of Safety Information Data Sources Jeremy Jokinen, PhD, MS Senior Director, Safety Decision Analytics AbbVie, Inc. Peter Verdru, MD Vice President, Head of Patient Safety UCB Biopharma S.P.R.L., Belgium
3:15-3:30PM	Closing Remarks
3:30PM	Conference Adjourned